Contract Service Directory


Company Headquarters

125 Sandy Drive
Newark, DE 19713
United States

Company Description

ISO/IEC 17025:2017 accredited, FDA registered, cGMP compliant microbiology service laboratory providing rapid and accurate analyses of bacteria, yeast & fungi. Specializing in identification & enumeration of pharmaceutical, probiotic, & environmental organisms using the latest technologies: DAN Sequencing, MALDI-TOF, & Fatty Acid Analysis.

Contract Service Directory

    Related Content

    • Bio News | Biosimilars
      Know the Challenges of Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best Practices for a Competitive Market
      Jerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18

    • Bio News | Biologics, Proteins, Vaccines | cGMP Manufacture | Industry News
      NIBRT, GE Healthcare Open SU Bio-Mfg. CoE

      NIBRT, GE Healthcare Open SU Bio-Mfg. CoE

      Aims to drive next-generation biomanufacturing expertise with a new training center

    • Breaking News | Drug Delivery | Industry News | Inspections
      Tapemark Passes Regulatory Hurdle

      Tapemark Passes Regulatory Hurdle

      Manufacturing facility completes successful FDA pre-approval and general GMP inspection

    • Inspections | Regulatory Affairs

      Warning Letters & Close-out Letters

      Why does it take so long to get a close-out letter?

    • Breaking News | Industry News | Inspections
      BioPharma Services Completes 3 FDA Inspections

      BioPharma Services Completes 3 FDA Inspections

      No Form 483’s reported

    • Breaking News | Facilities | Industry News | Inspections
      Frontida BioPharm Launches Expansion Efforts

      Frontida BioPharm Launches Expansion Efforts

      Comes on heels of receiving FDA clearance

    • Regulatory Affairs
      The FDA and Metrics

      The FDA and Metrics

      The Agency and industry continue to work together to achieve FDA’s objectives
      David Lonza, Lachman Consultant Services, Inc. 05.09.17

    • Breaking News | Clinical Trial Materials | Clinical Trials | Drug Development | Facilities | Industry News
      Carmell Therapeutics Expands Mfg. Capabilities

      Carmell Therapeutics Expands Mfg. Capabilities

      Will soon enter a Phase III study for its bone healing accelerant product

    • Regulatory Affairs

      Establishments, Identifications, Submissions and Beyond

      A closer look at electronic submissions of manufacturing establishment information (MEI).
      Sharif Ahmed, Lachman Consultants 04.03.17

    • Trump Picks New FDA Commish

      Combatting high drug prices and overregulation likely to be high on agenda
      Tim Wright, Editor 04.03.17

    • Bio News | Breaking News | Facilities | Fill/Finish | Industry News | Injectables | Parenterals

      Aptar Pharma Inaugurates Congers Site Expansion

      Facility will be used for injectable elastomeric component manufacturing

    • Capsules | Solid Dosage/Semi-solids

      Generic Drug Trends

      Industry faces tighter capacity, consolidation, and drug pricing uncertainty
      Edward S. Price, President, PCI 03.07.17

    • Regulatory Affairs

      Whither Washington?

      With a new administration, the future of the FDA may be the biggest wildcard in the outlook for CDMOs and their customers
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 03.07.17

    • Regulatory Affairs

      Challenges and Advantages of International Regulatory Inspections

      A look at the processes and approaches followed by FDA
      Daniel Barreto, Lachman Consultants 03.07.17

    • Aseptic Processing | Bio News | Breaking News | Facilities | Fill/Finish | Industry News | Inspections | Lyophilization

      LSNE Completes Two FDA Inspections

      FDA PAI and general GMP inspection of two aseptic manufacturing plants and QC laboratory completed successfully

    • Drug Development | Drug Discovery | Industry News

      BMS, GRAIL in Precision Medicine Pact

      BMS investment aims to advance pipeline with highly sensitive blood tests that detect cancer early

    • QA/QC | Regulatory Affairs
      FDA’s Quality Agreements Guidance

      FDA’s Quality Agreements Guidance

      Evaluation of FDA’s recently issued Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry
      Paul Mason, Ph.D., Director of Lachman Consultant Services, Inc. 01.26.17

    • Biologics, Proteins, Vaccines | Drug Discovery | Industry News

      Eurofins Genomics Expands Express Oligo Service

      Express Oligo service aims to allow more customers to receive primers in a shorter turnaround time